C-reactive protein (CRP) acts as a biomarker reflecting different degrees of inflammation. Accumulating reports have suggested that there is a close relationship between CRP and various cancers. However, the influence of CRP on the development of tongue squamous cell carcinoma (TSCC) remains unclear. The purpose of this study was to investigate the role of CRP in TSCC. The results of immunohistochemical staining and statistical analyses showed that CRP expression was associated with TSCC tumor size, lymph node metastasis and pathological differentiation. Cell Counting Kit-8 (CCK-8) assay revealed that CRP could enhance TSCC cell proliferation in a doseand time-dependent manner. Moreover, with CRP stimulation, proliferating cell nuclear antigen (PCNA) expression patterns presented a notable time-dependent up-regulation. In addition, CRP could enhance the invasion and migration of TSCC cells, as revealed by transwell and woundhealing assays, respectively. Annexin V-FITC/PI staining showed that CRP could protect TSCC cells from starvation-and drug-induced apoptosis. With CRP stimulation, the protein expression levels of phosphorylated protein kinase B (pAkt), phosphorylated mammalian target of rapamycin (pmTOR) and phosphorylated S6 ribosomal protein (pS6) were significantly increased, as demonstrated by western blot analysis. Our data suggest that CRP may play an important role in the development of TSCC. Moreover, the biological effects of CRP on TSCC cells might be related to Akt, mTOR, and S6.
Introduction
Cancer of the oral cavity is the sixth most common cancer worldwide. Tongue squamous cell carcinoma (TSCC) is one of the most prevalent histopathological types, accounting for 20%-40% of oral carcinomas [1, 2] . Patients with TSCC usually have poor prognoses and high mortality rates because of the high invasiveness and lymph node metastasis of TSCC [3] . Despite advances in treatment strategies involving surgery, chemotherapy, and radiotherapy, many patients may still suffer from eating disorders, impaired language functions and cancer-related death.
Currently, targeted molecular therapy has been applied in oral cancer patients. This treatment modality has few if any side effects on normal cells in the body [4] . Exploring cancer-associated factors and genes is important for the development of targeted cancer treatments.
Inflammatory responses play diverse roles at different stages of tumor development, including initiation, promotion, malignant conversion, invasion and metastasis [5] . Tumorigenesis and tumor development are related not only to the biological characteristics of tumors, but also to elements of inflammation in the tumor microenvironment. Many inflammatory factors, such as interleukin-6 (IL-6) [6] , IL-1β [7] , and tumor necrosis factor-α (TNF-α) [8] , are involved in various signaling pathways that potentiate TSCC progression. However, the precise mechanism of TSCC remains unknown, and other potential inflammatory factors might be involved in this process.
C-reactive protein (CRP) is a classical acute-phase reactant protein belonging to the pentraxin family. Members of this family are characterized by a cyclic pentameric structure. CRP consists of five identical subunits that form a planar ring, which confers very high stability to the protein. By binding to a variety of autologous and extrinsic ligands exposed on the membrane of injured, necrotic, and apoptotic cells, CRP potently activates the classical complement pathway, which might exacerbate tissue damage, leading to more severe diseases [9] . Accumulating evidence strongly suggested that CRP is an inflammatory marker and a direct cause of such diseases and conditions as atherosclerosis, myocardial infarction and bone fracture [10] [11] [12] . Recent studies showed that the serum CRP level is significantly higher in patients with tumors, such as hepatocellular carcinoma, lung cancer, and breast cancer [13] [14] [15] [16] . The serum CRP level was associated with tumor size, clinicopathological features and lymph node metastasis [17, 18] . Furthermore, CRP is also an important biomarker of tumor prognosis and treatment response [19] [20] [21] [22] [23] . In multiple myeloma, human CRP might bind activating Fcγ receptors and protect myeloma tumor cells from apoptosis [24] . These studies led to our hypothesis that CRP might play an important role in the development of TSCC.
Therefore, the purpose of this study was to investigate the correlation between CRP expression and TSCC and preliminarily explore the effects of CRP on TSCC cells, as well as the potentially related signaling molecules.
Materials and Methods

Clinical samples
This study was approved by the Ethics Committee of the School and Hospital of Stomatology, Shandong University (Jinan, China). A written consent form was obtained from each patient who underwent surgical resection at the School and Hospital of Stomatology, Shandong University between 2014 and 2016. Tongue tissue samples from 42 TSCC patients were collected with definitive demographic and clinicopathological records (Table 1) . Then, the samples were dehydrated through a graded alcohol series and embedded in paraffin.
Immunohistochemistry
The patient samples were stained with haematoxylin and eosin and classified histologically. The sections were deparaffinized in xylene, hydrated through a graded alcohol series, and washed in phosphatebuffered saline (PBS). Antigen retrieval was performed by treating the samples with 0.1% (w/v) trypsin (Zhongshan Company, Beijing, China). The activity of endogenous tissue peroxidase was blocked with 3% H 2 O 2 (Zhongshan Company). Normal goat serum (Zhongshan Company) was used to block non-specific binding. Then, the sections were incubated with anti-CRP antibody (1:100 dilution; Santa Cruz Biotech, Santa Cruz, USA) at 4°C overnight. Biotinylated goat antirabbit immunoglobulin G (IgG) and streptavidin-peroxidase conjugate (Zhongshan Company) were respectively incubated the sections at 37°C for 25 min. A diaminobenzidine solution (Zhongshan Company) was used to visualize localization. Finally, the sections were lightly counterstained with haematoxylin. Image-Pro Plus 6.0 software was used to determine the integrated optical density (IOD) of CRP staining quantitatively. CRP expression was determined by randomly selecting five tumor cell areas of each specimen.
Cell culture
The human TSCC cell lines CAL27 and SSC4 were obtained from the Chinese Academy of Sciences Committee Type Culture Collection Cell Bank (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, USA) supplemented with 10% fetal bovine serum (FBS; Gibco). Before processing, the cells were incubated in DMEM with 0.5% FBS for 24 h of starvation.
Cell proliferation assay
Cell growth was analyzed using Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan). After starvation, the suspended CAL27 and SCC4 cells (1 × 10 3 /well) were seeded in 96-well plates, and then the cells were cultured in complete medium (DMEM supplemented with 10% FBS) containing different concentrations of human recombinant CRP (dissolved in PBS, 0, 5, 10, 20, and 30 μg/ ml; Sigma, St Louis, USA) for 24 h. In addition, the cells were also stimulated with various concentrations of human recombinant CRP (5, 10, and 20 μg/ml) for different time (48, 36, 24, 12, 6 , and 0 h). Subsequently, the cells were treated with a 10% CCK-8 solution at 37°C for 2 h. The absorbance was measured at 450 nm. The control groups were obtained by substituting CRP with PBS.
Cell invasion assay
Cell invasiveness was measured using 24-well Biocoat cell culture (Corning Co, Corning, USA) inserts containing a polyethylene terephthalate membrane (8-μm pores) coated with Matrigel basement 
Cell migration assay
Cell migration ability was monitored by wound-healing assay. The CAL27 cells were seeded in 6-well plates and cultured till cell monolayer was formed. A sterile micropipette tip was then used to create a scratch on the cell monolayer. The cells in the plates were further incubated with different culture mediums (DMEM without FBS, serum-free DMEM with 10 μg/ml CRP, and DMEM with 10% FBS) for up to 18 h, and the wound width was then measured by microscopy at 0, 6, 12, and 18 h to assess cell migration. The control groups were obtained by substituting CRP with PBS.
Cell apoptosis assay
Annexin V-FITC/PI apoptosis detection kit (BD Biosciences, San Jose, USA) was used to measure the number of apoptotic cells after the cells were treated with different conditions. In order to induce the cells apoptosis, serum-free DMEM for starvation-induced apoptosis and complete medium (DMEM supplemented with 10% FBS) with Cisplatin (DDP; dissolved in PBS; 2 μg/ml) for drug-induced apoptosis were used to culture CAL27 and SCC4 cells. Briefly, cells were seeded in six-well plates and cultured in different mediums [serum-free DMEM, serum-free DMEM + CRP (10 μg/ml); complete medium (DMEM supplemented with 10% FBS), complete medium + CRP (10 μg/ml), complete medium + DDP (2 μg/ml), complete medium + DDP (2 μg/ml) + CRP (10 μg/ml)] for 24 h. Then, cells were trypsinized and washed twice with cold PBS, and then resuspended in 1× Annexin V binding solution in a volume of 100 μl with 3 μl Annexin V, FITC and 3 μl PI solution. The cells were gently mixed and incubated in the dark for 15 min at room temperature. Following that, a quota of 1× Annexin V binding solution (400 μl) was added to each test tube and the number of apoptotic cells was quantified by flow cytometry (BD FACSAria TM II) within 1 h. The control groups were obtained by substituting CRP with PBS.
Western blot analysis
To further investigate the influence of CRP on the proliferation of CAL27 cells, western blot analysis was also used to detect the expression patterns of proliferating cell nuclear antigen (PCNA) during CRP (10 μg/ml) stimulation for different time (48, 36, 24, 12, 6 , and 0 h). In addition, to study the potentially related signaling molecules, CAL27 cells were cultured in serum-free DMEM containing CRP (10 μg/ml) for 120, 60, 30, 15, and 0 min. After being treated with CRP, the cells were rinsed with PBS and lysed in ice-cold lysis buffer. Protein concentrations were measured using a Bicinchoninic Acid Protein Assay Kit (Pierce, Rockford, USA). A total of 20 μg of protein was loaded for separation by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and were then electrotransferred to polyvinylidene fluoride membranes (Millipore, Billerica, USA). After being blocked, the membranes were incubated with various primary antibodies (anti-PCNA, anti-Akt, anti-mTOR, antipmTOR, anti-S6, 1:1000; anti-pS6, anti-β-actin, 1:2000; anti-pAkt, 1:500; Cell Signaling Technology, Beverly, USA) at 4°C overnight. After extensive wash, the membranes were incubated with HRPconjugated anti-rabbit IgG antibody (1:5000; Cell Signaling Technology) for 1 h. Protein bands were visualized on Canon (Tokyo, Japan) films using an enhanced chemiluminescence substrate solution (Millipore) according to the manufacturer's instructions. The control groups were obtained by substituting CRP with PBS.
Statistical analysis
Each experiment in this study was performed three times using independent cells or tissue samples. Data were collected from experiments in triplicate. The mean and standard deviation (SD) were calculated. Data are presented as the mean ± SD. SPSS version 17 was used to analyze the differences between groups. Significant differences between groups were evaluated using one-way ANOVA or Student's t-test with P < 0.05.
Results
CRP expression in TSCC tissue and the correlation between CRP expression level and clinicopathological parameters in patients with TSCC
The expression level of CRP in different TSCC tissues was determined by immunohistochemistry. Our results showed positive staining for CRP in TSCC tissue, which was primarily localized in the cytosol of tumor cells. Furthermore, the CRP staining in moderately and poorly differentiated tumor tissues was stronger than that in well-differentiated tumor tissues (Fig. 1) .
The statistical analysis showed that the tumor CRP expression level was positively associated with both tumor size (P = 0.003) and pathological differentiation (P < 0.001), whereas no significant relationship was found between the CRP expression level and patient gender (P = 0.620) or age (P = 0.550). Moreover, CRP was strongly expressed in those patients with lymph node metastasis (P < 0.001) ( Table 1) .
CRP enhances TSCC cell proliferation, invasion and migration
The CCK-8 assay showed that CRP significantly enhanced TSCC cell proliferation in a dose-and time-dependent manner ( Fig. 2A,B) . In addition, 10 μg/ml was found to be the significantly effective concentration of CRP; increasing the CRP concentration from 10 to 30 μg/ml did not result in greater proliferation effects ( Fig. 2A) . Thus, a CRP concentration of 10 μg/ml was chosen as the effective concentration for further research. With CRP treatment for up to 24 h, the growth rate of TSCC cells was significantly increased. However, the growth ability of TSCC cells was inhibited after 24 h (Fig. 2B) . Therefore, the stimulation time of 24 h was chosen as the optimum time of CRP treatment on TSCC cell proliferation. PCNA expression presented a notable time-dependent up-regulation when the stimulation time of CRP was increased from 0 to 24 h. However, with the time extended to 36 and 48 h, the levels of PCNA expression were decreased (P < 0.05; Fig. 2C ). Both the results of CCK-8 and PCNA expression patterns suggested that 24 h of CRP treatment could significantly enhance the TSCC cell proliferation at a concentration of 10 μg/ml. Transwell chamber and . CRP enhances TSCC cell proliferation in a dose-and time-dependent manner (A) The concentration of 10 μg/ml was found to be the significantly effective concentration of CRP; increasing the CRP concentration from 10 μg/ml to 30 μg/ml did not result in greater proliferation effects. (B) With CRP treatment for up to 24 h, the growth rate of TSCC cells was significantly increased. However, the growth of TSCC cells was inhibited after 24 h. (C) Western blot analysis showed that the expression level of PCNA was up-regulated when TSCC cells were stimulated with CRP from 0 to 24 h. With the time extended to 36 and 48 h, the level of PCNA expression was decreased. Data are presented as the mean ± SD. *P < 0.05.
wound-healing assays were used to study the effects of CRP on TSCC cell invasion and migration. Our results indicated that CRP increased TSCC cell invasion and migration. Compared with the negative control groups, more cells were found on the lower surface of the membrane after treatment with CRP (10 μg/ml) for 24 h (P < 0.05; Fig. 3 ). In addition, the wound-healing assay showed that the distance migrated by cells after CRP treatment for 6, 12, and 18 h was~0.3-, 1-, and 0.5-fold greater than that migrated by cells in the negative control groups, respectively. Cells with CRP treatment could migrate at a higher rate than cells in the control groups (P < 0.05; Fig. 4 ).
CRP protects TSCC cells from apoptosis
The percentage of starvation-induced apoptotic cells cultured in serum-free DMEM was 17.9% for CAL27 cells and 16.1% for SCC4 cells. With the addition of CRP, the percentage of apoptotic cells dropped to 10.8% and 8.4%, respectively (Fig. 5A) . Next, DDP was used to induce TSCC cells apoptosis. In the presence of 2 μg/ml DDP, the percentage of apoptotic cells cultured in complete medium (DMEM with 10% FBS) increased from 1.5% to 19.3% in CAL27 cells, and from 3.4% to 17.1% in SCC4 cells. However, when the CRP was added, the percentage of apoptotic cells decreased to 8.1% and 6.9%, respectively (Fig. 5B) . With the addition of CRP (10 μg/ml), there was an~50% decrease in apoptotic cells compared with the control (P < 0.05; Fig. 5 ).
CRP induces Akt, mTOR and S6 phosphorylation
Western blot analysis was then used to examine the expression patterns of relevant molecules including pAkt, pmTOR and pS6. As shown in Fig. 6 , the expression levels of pAkt and pmTOR were upregulated with CRP treatment for up to 1 h, and the ratios of pAkt/ Akt and pmTOR/mTOR were significantly increased. Moreover, with CRP stimulation for up to 30 min, the expression of pS6 was also significantly increased, and the ratio of pS6/S6 was increased bỹ 30%. However, when the treatment time was extended to 2 h, the protein expression levels of pAkt, pmTOR and pS6 were downregulated, and the ratios of pAkt/Akt, pmTOR/mTOR, and pS6/S6 were also decreased (P < 0.05; Fig. 6 ).
Discussion
CRP is a classical acute-phase reactant protein that can bind with and activate cell surface receptors, such as FcγRI/II and FcαRI [25, 26] . CRP has been widely used not only as a predictive marker of infection, cardiovascular diseases and hypertension, but also as a risk marker of various cancers. However, the influence of CRP on the development of cancer has seldom been investigated. In this study, immunohistochemical staining showed that CRP expression was up-regulated in TSCC tissues and correlated with clinicopathological features. CRP stimulation significantly promoted the proliferation, invasion and migration of TSCC cells through the Akt, mTOR, and S6 signaling pathways. Moreover, CRP could protect TSCC cells from starvation-and druginduced apoptosis. These findings indicate that CRP may play important roles in tumor development, progression, and metastasis. . CRP enhances the migration of TSCC cells The wound-healing assay showed that the distance migrated by cells after CRP treatment for 6, 12, and 18 h was~0.3-, 1-, and 0.5-fold greater than that migrated by cells in the negative control groups, respectively. Statistical analysis of the migration distance showed that cells with CRP treatment could migrate at a higher rate than the control groups. Data are presented as the mean ± SD. *P < 0.05. Current cancer etiology studies suggest that chronic inflammation contributes to cancer development and progression [27] . There is a bidirectional relationship between carcinogenesis and chronic inflammation: tumor cells attract immune cells, thereby promoting the production of cytokines and chemokines and creating an inflammatory tumor microenvironment, while inflammatory components might initiate and promote tumor development [28] . Inflammatory components in the tumor microenvironment, such as IL-6, IL-1β, and TNF-α [29] , have been reported to play important roles in both the carcinogenesis and progression of tongue carcinoma. Therefore, anti-inflammation therapy has been considered as an anti-cancer therapeutic opportunity.
Just as other inflammatory mediators, CRP is also involved in inflammatory components in the tumor microenvironment. It is generally agreed that in response to inflammation, trauma, and tissue damage, CRP is synthesized by hepatocytes and secreted into the tumor microenvironment via the blood circulation. The serum CRP level is higher in patients with chronic diseases, heart diseases or tumors than in healthy controls [10] [11] [12] [13] [14] [15] [16] . However, to the best of our knowledge, the present attentions are mainly paid to diagnostic and prognostic values of CRP, while the influence of CRP on the development of cancers including TSCC has seldom been investigated. Therefore, we first detected CRP expression in TSCC tissues and found that CRP expression was up-regulated and correlated with clinicopathological features. Biological behaviors, including cell proliferation, cell invasion, migration, and apoptosis, are important factors that affect tumor development, progression, and prognosis. Our results showed that CRP significantly promotes TSCC cell proliferation, invasion, and migration in vitro. With the addition of CRP, the percentage of apoptotic TSCC cells was decreased by~50% compared with that in the control. These data indicated that CRP might act not only as a diagnostic and prognostic marker, but also as a potential promoter for TSCC development, progression, and metastasis.
Intriguingly, the results of CCK-8 assay and PCNA expression patterns showed that CRP could decrease the growth rate of TSCC cells when the treatment time was extended from 24 to 36 and 48 h, indicating that CRP might also play a negative regulatory role in TSCC cells after 24 h. These findings led to our hypothesis that CRP may have dual functions: a carcinogene as well as a tumor suppressor gene in TSCC cells. However, this hypothesis needs to be confirmed by further research. In addition, our immunohistochemical staining results showed that CRP is primarily localized in the cytosol rather than in the cell matrix, suggesting that cancer cells might produce and secrete CRP into the tumor microenvironment to potentiate tumor progression. This observation is consistent with a previous study on breast cancer which reported that the inflammatory lipid sphingosine-1-phosphate could up-regulate CRP expression and secretion in MCF10A cells [30] . However, the regulatory effect of endogenous CRP of TSCC cells remains to be further explored.
The Akt/mTOR signaling pathway is pivotal in multiple physiological and pathological process, including cell cycle regulation, proliferation, differentiation, and migration, as well as angiogenesis [31] . Akt serves as an essential regulator of both protein synthesis and degradation through modulating mTOR pathway activity [32] . Once Akt is activated through the phosphorylation of its serine and threonine residues at positions 308 and 473, pAkt phosphorylates mTOR directly in a rapamycin-sensitive complex. Then, phosphorylated mTOR initiates a cascade of downstream signaling events [33, 34] . Blockade of the Akt/mTOR signaling pathway has been considered useful in the treatment of cancers [35, 36] . Our results showed that CRP could significantly up-regulate the expression levels of pAkt, pmTOR, and pS6. The protein expression ratios of pAkt/Akt, pmTOR/mTOR, and pS6/S6 were also increased. These results indicated that Akt, mTOR, and S6 might be important players in CRP-mediated TSCC cell proliferation, invasion, and migration. However, after 2 h of CRP stimulation, these protein levels were substantially decreased. These data suggested that other signaling pathways and molecules might be involved in this process.
In conclusion, our findings suggest that CRP may not only be a potential biomarker for the diagnosis and prognosis assessment of TSCC, but also play an important role in the development of TSCC. In addition, Akt, mTOR, and S6 might be involved in the regulatory signaling pathways through which CRP could promote the development of TSCC. However, the role of CRP and its precise mechanism in TSCC need to be further explored. Figure 6 . CRP treatment remarkably induces Akt, mTOR and S6 phosphorylation With 10 μg/ml CRP stimulation, the expression levels of pAkt, pmTOR were significantly up-regulated for up to 1 h, and the expression of pS6 was significantly up-regulated for up to 30 min. When the treatment time was extended to 2 h, the protein expression levels of pAkt, pmTOR and pS6 were down-regulated. Data are presented as the mean ± SD. *P < 0.05.
